 Risk and reward are two of the most commonly used words in investing. The two are symbiotic and complement each other perfectly. Where there is more risk, the reward is likely to be more abundant. Of course, the equation works the other way too: less risk, probably less reward.The thesis is simple: a company such as Google is likely a pretty safe place for an investment. But with a market cap of $1 trillion, how much value can the company add to its share price? On the other hand, investing in a fledgling biotech with life-changing treatments in the pipeline could potentially see an investment yield extraordinary returns. Let's not forget, though, this sort of investment also carries a significant amount of risk with it.With this in mind, TipRanks' Stock Screener pointed us in the direction of three Healthcare stocks the experts on the Street think could soar in the year ahead. And by soar, we mean at least double their current value. The risk here as an investor is higher, but as we know by now, so are the possible rewards. As an added bonus, all three currently have a Strong Buy consensus rating from the Street. Let's take a look at the data.ProQR Therapeutics (PRQR)ProQR's back story is unusual. The company was founded after CEO Daniel de Boer's newborn son was diagnosed with cystic fibrosis. De Boer, with the help of several co-founders, then formed ProQR - a biotech with a focus on providing new medicines for rare diseases. There are approximately 7,000 rare diseases in the world today, and only 400 currently have treatmen
|
Private Label